A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum- sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup ( GCIG)

被引：0
|
作者：
Pujade-Lauraine, E.
Mahner, S.
Kaern, J.
Gebski, V.
Heywood, M.
Vasey, P.
Reinthaller, A.
Vergote, I.
Pignata, S.
Ferrero, A.
机构：
[1] GINECO, Paris, France
[2] AGO OVAR, Hamburg, Germany
[3] NSGO, Oslo, Norway
[4] ANZGOG, Sydney, NSW, Australia
[5] NCIC, CTG, Vancouver, BC, Canada
[6] ANZGOG, Queensland, Australia
[7] AGO Austria, Vienna, Austria
[8] Eortc Data Ctr, Louvain, Belgium
[9] MITO, Naples, Italy
[10] MANGO, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)
    Wagner, U.
    Burges, A.
    Kurzeder, C.
    Beckmann, M. W.
    Belau, A.
    Hanker, L.
    Canzler, U.
    Richter, B.
    Sehouli, J.
    Pujade-Lauraine, E.
    ONKOLOGIE, 2010, 33 : 2 - 2
  • [2] A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)
    Pujade-Lauraine, E.
    Mahner, S.
    Kaern, J.
    Gebski, V.
    Heywood, M.
    Vasey, P.
    Reinthaller, A.
    Vergote, I.
    Pignata, S.
    Ferrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [3] Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
    Kurtz, J. E.
    Kaminsky, M. C.
    Floquet, A.
    Veillard, A. S.
    Kimmig, R.
    Dorum, A.
    Elit, L.
    Buck, M.
    Petru, E.
    Reed, N.
    Scambia, G.
    Varsellona, N.
    Brown, C.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2417 - 2423
  • [4] Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
    Wagner, U.
    Marth, C.
    Largillier, R.
    Kaern, J.
    Brown, C.
    Heywood, M.
    Bonaventura, T.
    Vergote, I.
    Piccirillo, M. C.
    Fossati, R.
    Gebski, V.
    Lauraine, E. P.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 588 - 591
  • [5] Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
    U Wagner
    C Marth
    R Largillier
    J Kaern
    C Brown
    M Heywood
    T Bonaventura
    I Vergote
    M C Piccirillo
    R Fossati
    V Gebski
    E P Lauraine
    British Journal of Cancer, 2012, 107 : 588 - 591
  • [6] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial.
    Mahner, S.
    Meier, W.
    Du Bois, A.
    Brown, C.
    Lorusso, D.
    Ferrero, A.
    Cretin, J.
    Havsteen, H.
    Bessette, P.
    Angleitner-Boubenizek, L.
    Vergote, I. B.
    Vasey, P. A.
    Gebski, V.
    Slama, B.
    Herrstedt, J.
    Kaizer, L.
    Georgoulopoulos, A.
    Reed, N.
    Wagner, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial
    Mahner, Sven
    Meier, Werner
    du Bois, Andreas
    Brown, Chris
    Lorusso, Domenica
    Dell'Anna, Tiziana
    Cretin, Jacques
    Havsteen, Hanne
    Bessette, Paul
    Zeimet, Alain G.
    Vergote, Ignace
    Vasey, Paul
    Pujade-Lauraine, Eric
    Gladieff, Laurence
    Ferrero, Annamaria
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) : 352 - 358
  • [8] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
    Gladieff, L.
    Ferrero, A.
    De Rauglaudre, G.
    Brown, C.
    Vasey, P.
    Reinthaller, A.
    Pujade-Lauraine, E.
    Reed, N.
    Lorusso, D.
    Siena, S.
    Helland, H.
    Elit, L.
    Mahner, S.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1185 - 1189
  • [9] A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients
    Vasey, P.
    Largillier, R.
    Gropp, M.
    Gebski, V.
    Sandvei, R.
    Elit, L.
    Angleitner-Boubezinek, L.
    Reed, N.
    Pignata, S.
    Ferrero, A. M.
    EJC SUPPLEMENTS, 2009, 7 (03): : 11 - 11
  • [10] PHASE 2, RANDOMIZED CONTROLLED STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CARBOPLATIN VERSUS GEMCITABINE AND CARBOPLATIN IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (GOTIC003/INTERGROUP STUDY)
    Fujiwara, H.
    Ushijima, K.
    Nagao, S.
    Takei, Y.
    Shimada, M.
    Takano, M.
    Yoshino, K.
    Kawano, Y.
    Hirashima, Y.
    Nagase, S.
    Nishio, S.
    Nishikawa, T.
    Ito, K.
    Shoji, T.
    Kimura, E.
    Takano, T.
    Sugiyama, T.
    Kigawa, J.
    Fujiwara, K.
    Suzuki, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 48 - 48
12345